Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

Comparable outcomes in patients aged ≥70 vs. <70 undergoing allogeneic transplantation with fludarabine and melphalan conditioning and post-transplant cyclophosphamide

Howard Chang, Staci Williamson, Daniel Chandra, Andy Chen, Rachel Cook, Amrita Desai, Arpita Gandhi, Brandon Hayes-Lattin, Curtis Lachowiez, Jessica Leonard, Richard Maziarz, Laura Newell, Jennifer Saultz, Ronan Swords, Elie Traer, Gabrielle Meyers

Blood (2025) 146 (Supplement 1): 6085.

https://doi.org/10.1182/blood-2025-6085

Published: 2025

Journal Articles

High-dose anakinra to treat refractory immune effector cell-associated neurotoxicity syndrome in CAR T-cell therapy recipients

Blood (2025) 146 (Supplement 1): 928.

https://doi.org/10.1182/blood-2025-928

Published: 2025

Journal Articles

The impact of first line tyrosine kinase inhibitors (TKI) on the development of resistance mutations in patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)

Virginia Tan, Jean Sabile, Amrita Desai, Arpita Gandhi, Jennifer Saultz, Gabrielle Meyers, Laura Newell, Rachel Cook, Elie Traer, Curtis Lachowiez, Ronan Swords, Richard Maziarz, Theodore Braun, Brandon Hayes-Lattin, Jessica Leonard

Blood (2025) 146 (Supplement 1): 3372.

https://doi.org/10.1182/blood-2025-3372

Published: 2025

Journal Articles

Venetoclax in combination with dasatinib, prednisone, rituximab and blinatumomab for the upfront treatment of adults with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), Results from a Phase 1B study

Blood (2025) 146 (Supplement 1): 3354.

https://doi.org/10.1182/blood-2025-3354

Published: 2025

Journal Articles

Large B-cell lymphoma after CD19-CAR-T failure: Updated real-world outcomes, prognostic factors, and prediction models

Smith Kungwankiattichai, Sanjog Bastola, Manoj Rai, Amrita Desai, Andy Chen, Craig Okada, Brandon Hayes-Lattin, Stephen Spurgeon, Tanaya Shree, Weerapat Owattanapanich, Staci Williamson, Bashi Ratterree, Rachel Bixler, Chi Phan, Robert Ahrenkiel, Richard Maziarz

Blood (2025) 146 (Supplement 1): 3726.

https://doi.org/10.1182/blood-2025-3726

Published: 2025

Journal Articles

Telehealth based virtual consult visits and in-person consult visits provide comparable time to HLA-typing and preliminary donor search in patients referred for allogeneic hematopoietic cell transplantation

Blood (2025) 146 (Supplement 1): 1083.

https://doi.org/10.1182/blood-2025-1083

Published: 2025

Journal Articles

Low adherence to cervical cancer screening guidelines among women survivors after allogeneic hematopoietic cell transplantation: Predictors and practice gaps from a single-center analysis

Prajna Woonnimani, Amanda Bruegl, Haley Burns, Jessica Currier, Kate Bolten, Talia Frost-Belansky, Emily Van Houweling, Jennifer Saultz, Andy Chen, Jessica Leonard, Amrita Desai, Staci Williamson, Laura Newell, Brandon Hayes-Lattin, Gabrielle Meyers, Richard Maziarz, Rachel Cook, Arpita Gandhi

Blood (2025) 146 (Supplement 1): 7784.

https://doi.org/10.1182/blood-2025-7784

Published: 2025

Journal Articles

Comparison of 80 mg/kg vs. 100 mg/kg post-transplant cyclophosphamide dose with flu/mel and allogeneic transplant: Less is not more

Blood (2025) 146 (Supplement 1): 4252.

https://doi.org/10.1182/blood-2025-4252

Published: 2025

Journal Articles

Preliminary safety and efficacy results of A phase ib investigation of the LSD1 inhibitor iadademstat (ORY-1001) in combination with azacitidine and venetoclax in newly-diagnosed AML

Curtis Lachowiez, Andy Kaempf, Carolyn Lehn, Tara Lundberg Williams, Gabriella Sheldon, Jessica Leonard, Gabrielle Meyers, Arpita Gandhi, Jennifer Saultz, Brandon Hayes-Lattin, Richard Maziarz, Rachel Cook, Ronan Swords, Gordon Mills, Theodore Braun

Blood (2025) 146 (Supplement 1): 1649.

https://doi.org/10.1182/blood-2025-1649

Published: 2025

Journal Articles

FluMel100 with post-transplant cyclophosphamide: A safe and effective regimen for patients aged ≥75 years with MDS and AML

Blood (2025) 146 (Supplement 1): 7744.

https://doi.org/10.1182/blood-2025-7744

Published: 2025

Journal Articles

Immunophenotypic Markers CD7 and CD56 Improve Risk Stratification of Frontline Hypomethylating Agents + Venetoclax in Newly Diagnosed AML

Curtis A Lachowiez, Daniel T Peters, Jacob Fang, Andy Kaempf, Jessica T. Leonard, Laura F. Newell, Arpita Gandhi, Gabrielle Meyers, Brandon Hayes-Lattin, Richard T. Maziarz, Rachel J. Cook, Elie Traer, Ronan T. Swords, Jeffrey W. Tyner, Joshua F Zeidner, Daniel A Pollyea, Jennifer N. Saultz

Blood (2024) 144 (Supplement 1): 4314.

https://doi.org/10.1182/blood-2024-202118

Published: 2024

Journal Articles

Purine-Analog Based Intensive Chemotherapy (IC) Combined with Venetoclax (VEN) Is Highly Active in Newly Diagnosed (ND) and Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Blood (2024) 144 (Supplement 1): 2887.

https://doi.org/10.1182/blood-2024-203361

Published: 2024

Journal Articles

NCAM1 (CD56) As a Predictor of Response to Standard Intensive Induction in Newly Diagnosed Acute Myeloid Leukemia

Jennifer N. Saultz, Manoj Rai, Andy Kaempf, Sanjog Bastola, Hyun Cho, Nicola Long, Curtis A. Lachowiez, Gabrielle Meyers, Jessica T. Leonard, Arpita Gandhi, Laura F. Newell, Brandon Hayes-Lattin, Richard T. Maziarz, Rachel J. Cook, Elie Traer, Ronan T. Swords, Jeffrey W. Tyner

Blood (2024) 144 (Supplement 1): 2859.

https://doi.org/10.1182/blood-2024-211860

Published: 2024

Journal Articles

Impact of Social Determinants of Health on Access to Blood and Marrow Transplantation for Acute Myeloid Leukemia

Somya Khare, Rachel J. Cook, Amrita Desai, Arpita Gandhi, Kelli Goslee, Brandon Hayes-Lattin, Curtis A Lachowiez, Jessica T. Leonard, Richard T. Maziarz, Gabrielle Meyers, Laura F. Newell, Jennifer N. Saultz, Ronan T. Swords, Elie Traer, Eneida R Nemecek

Blood (2024) 144 (Supplement 1): 2292.

https://doi.org/10.1182/blood-2024-209407

Published: 2024

Journal Articles

Likelihood of finding an 8/8 HLA-matched unrelated donor (Donor Search Prognosis) is not associated with survival: Primary results from BMT CTN 1702

Blood (2024) 144 (Supplement 1): 695.

https://doi.org/10.1182/blood-2024-200833

Published: 2024

Journal Articles

PTPN11 Mutations Are Associated with Shorter Survival in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax

Vishvaas I Ravikumar, Jessica T. Leonard, Laura F. Newell, Arpita Gandhi, Gabrielle Meyers, Brandon Hayes-Lattin, Richard T. Maziarz, Rachel J. Cook, Elie Traer, Ronan T. Swords, Jennifer N. Saultz, Jeffrey W. Tyner, Mael Heiblig, Joshua F Zeidner, Daniel A Pollyea, Curtis A Lachowiez

Blood (2024) 144 (Supplement 1): 4312.

https://doi.org/10.1182/blood-2024-201231

Published: 2024

Journal Articles

Results of a Phase 1 Trial Testing the Novel Combination Therapy of Venetoclax and Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia Patients

Blood (2023) 142 (Supplement 1): 1515.

https://doi.org/10.1182/blood-2023-191166

Published: 2023

Journal Articles

Prognostic Significance of NCAM1 (CD56) Expression in AML Patients Treated with HMA+Venetoclax

Blood (2023) 142 (Supplement 1): 5762.

https://doi.org/10.1182/blood-2023-188311

Published: 2023

Journal Articles

Access to Chimeric Antigen T-Cell Receptor (CAR-T) Therapies for Patients with Non-Hodgkin Lymphoma (NHL) in the Catchment Area of Oregon

Somya Khare, Staci Williamson, Brittany O'Barr, Levanto Schachter, Andy Chen, Brandon Hayes-Lattin, Jessica T. Leonard, Amrita Desai, Peter Ferreira-Gandolfo, Denise Lackey, Kevin Christmas, Richard T Maziarz, Eneida R Nemecek

Blood (2023) 142 (Supplement 1): 2405.

https://doi.org/10.1182/blood-2023-177864

Published: 2023

Journal Articles

A Phase I/II Study to Investigate the Addition of Venetoclax to Dasatinib and Steroids in Patients with Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL): The Venda Trial, in Progress

Jessica T. Leonard, Rachel Cook, Laura F. Newell, Arpita Gandhi, Ronan T. Swords, Christopher A. Eide, Brandon Hayes-Lattin, Kara Johnson, Elie Traer, Stephen E. Kurtz, Jennifer N. Saultz, Cristina Tognon, Jeffrey W Tyner, Curtis A. Lachowiez

Blood (2023) 142 (Supplement 1): 1512.

https://doi.org/10.1182/blood-2023-188313

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Comparable outcomes in patients aged ≥70 vs. <70 undergoing allogeneic transplantation with fludarabine and melphalan conditioning and post-transplant cyclophosphamide

High-dose anakinra to treat refractory immune effector cell-associated neurotoxicity syndrome in CAR T-cell therapy recipients

The impact of first line tyrosine kinase inhibitors (TKI) on the development of resistance mutations in patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)

Venetoclax in combination with dasatinib, prednisone, rituximab and blinatumomab for the upfront treatment of adults with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), Results from a Phase 1B study

Large B-cell lymphoma after CD19-CAR-T failure: Updated real-world outcomes, prognostic factors, and prediction models

Telehealth based virtual consult visits and in-person consult visits provide comparable time to HLA-typing and preliminary donor search in patients referred for allogeneic hematopoietic cell transplantation

Low adherence to cervical cancer screening guidelines among women survivors after allogeneic hematopoietic cell transplantation: Predictors and practice gaps from a single-center analysis

Comparison of 80 mg/kg vs. 100 mg/kg post-transplant cyclophosphamide dose with flu/mel and allogeneic transplant: Less is not more

Preliminary safety and efficacy results of A phase ib investigation of the LSD1 inhibitor iadademstat (ORY-1001) in combination with azacitidine and venetoclax in newly-diagnosed AML

FluMel100 with post-transplant cyclophosphamide: A safe and effective regimen for patients aged ≥75 years with MDS and AML

Immunophenotypic Markers CD7 and CD56 Improve Risk Stratification of Frontline Hypomethylating Agents + Venetoclax in Newly Diagnosed AML

Purine-Analog Based Intensive Chemotherapy (IC) Combined with Venetoclax (VEN) Is Highly Active in Newly Diagnosed (ND) and Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

NCAM1 (CD56) As a Predictor of Response to Standard Intensive Induction in Newly Diagnosed Acute Myeloid Leukemia

Impact of Social Determinants of Health on Access to Blood and Marrow Transplantation for Acute Myeloid Leukemia

Likelihood of finding an 8/8 HLA-matched unrelated donor (Donor Search Prognosis) is not associated with survival: Primary results from BMT CTN 1702

PTPN11 Mutations Are Associated with Shorter Survival in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax

Results of a Phase 1 Trial Testing the Novel Combination Therapy of Venetoclax and Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia Patients

Prognostic Significance of NCAM1 (CD56) Expression in AML Patients Treated with HMA+Venetoclax

Access to Chimeric Antigen T-Cell Receptor (CAR-T) Therapies for Patients with Non-Hodgkin Lymphoma (NHL) in the Catchment Area of Oregon

A Phase I/II Study to Investigate the Addition of Venetoclax to Dasatinib and Steroids in Patients with Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL): The Venda Trial, in Progress

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only